Tucatinib
This oral targeted therapy is a HER2-specific tyrosine kinase inhibitor used in combination with trastuzumab and capecitabine to treat HER2-positive breast cancer that has spread to the brain or other parts of the body, particularly after prior HER2-based therapy. It is notable for its ability to penetrate the blood-brain barrier, making it effective against brain metastases. Diarrhea and liver enzyme elevations are common side effects that require monitoring.
Peso molecular
480,5000 g/mol
LogP
4,00
TPSA
111,00 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Mecanismo de acción
Targets the HER2 (ErbB2) receptor tyrosine kinase, blocking HER2-mediated signaling that drives proliferation in HER2-overexpressing cancer cells.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Targets the HER2 (ErbB2) receptor tyrosine kinase, blocking HER2-mediated signaling that drives proliferation in HER2-overexpressing cancer cells.
Estructura 2D
Cite this structure
Embed this structure
SMILES
Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1
InChI
InChI=1S/C26H24N8O2/c1-16-10-17(5-7-22(16)36-19-8-9-34-23(12-19)28-15-30-34)31-24-20-11-18(4-6-21(20)27-14-29-24)32-25-33-26(2,3)13-35-25/h4-12,14-15H,13H2,1-3H3,(H,32,33)(H,27,29,31)
Molecular Formula
C26H24N8O2
HBD / HBA
2 / 8
Enlaces Rotables
6
Átomos Pesados
36
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
This oral targeted therapy is a HER2-specific tyrosine kinase inhibitor used in combination with trastuzumab and capecitabine to treat HER2-positive breast cancer that has spread to the brain or other parts of the body, particularly after prior HER2-based therapy. It is notable for its ability to penetrate the blood-brain barrier, making it effective against brain metastases. Diarrhea and liver enzyme elevations are common side effects that require monitoring.
Targets the HER2 (ErbB2) receptor tyrosine kinase, blocking HER2-mediated signaling that drives proliferation in HER2-overexpressing cancer cells.
Yes, Tucatinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989868. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 51039094. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tucatinib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tucatinib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tucatinib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tucatinib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tucatinib"></drugfyi-drug>